Lloyd Industries v. Datrend Systems: Voluntary Dismissal in ESU Analyzer Patent Dispute
Que souhaitez-vous faire ensuite ?
Choisissez votre parcours en fonction de vos besoins actuels :
📋 Résumé de l'affaire
| Nom de l'affaire | Lloyd Industries, Inc. et al. v. Datrend Systems, Inc. |
| Numéro de dossier | 1:23-cv-00998 (W.D. Tex.) |
| Tribunal | Tribunal fédéral de première instance pour le district ouest du Texas |
| Durée | Aug 2023 – Mar 2024 208 days |
| Résultat | Rejeté avec préjudice |
| Brevets en cause | |
| Produits incriminés | Datrend Systems’ vPad-RF ESU Analyzer |
Aperçu du dossier
Les parties
⚖️ Demandeurs
Both companies operate in the medical equipment testing and safety compliance space, where precision instruments and regulatory alignment are core competitive differentiators.
🛡️ Défendeur
A Canadian-based manufacturer known for its line of medical device safety testers and biomedical test equipment.
Le brevet en cause
The asserted patent, **U.S. Patent No. 9,883,903 B1** (Application No. 14/702,385), covers technology relevant to the testing and analysis of electrosurgical unit performance. ESU analyzers measure high-frequency electrical output used in surgical cutting and coagulation equipment, placing this patent squarely within the medical device testing patent landscape — an area experiencing increased enforcement activity as healthcare technology investment grows.
- • US 9,883,903 B1 — Technology for testing and analysis of electrosurgical unit performance
Developing medical device testing equipment?
Check if your product might infringe this or related patents before launch.
Le verdict et l'analyse juridique
Résultat
On March 15, 2024, plaintiffs Lloyd Industries and BC Group Int’l filed a notice of voluntary dismissal with prejudice pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(i). The court confirmed closure on March 18, 2024. No damages were awarded, no injunctive relief was issued, and no settlement terms have been publicly disclosed.
Principales questions juridiques
The case was filed as a straightforward patent infringement action — no validity challenges, declaratory judgment counterclaims, or IPR petitions appear in the available case record. The dismissal with prejudice, entered before Datrend formally engaged through counsel, raises several strategic questions for practitioners:
- • Pre-answer dismissal dynamics: Under Rule 41(a)(1)(A)(i), a plaintiff retains unilateral dismissal rights before the defendant serves an answer or summary judgment motion. This right disappears once the defendant formally responds, making the timing of Datrend’s non-appearance legally significant.
- • “With prejudice” designation: Unlike a without-prejudice dismissal, this termination bars plaintiffs from re-filing the same claims against Datrend on the same patent. This is a meaningful concession that distinguishes this outcome from a strategic retreat and re-filing.
- • No disclosed settlement: The absence of any disclosed license, settlement, or consent judgment leaves the resolution terms — if any exist — entirely private.
As the court’s order noted, citing In re Amerijet Int’l, Inc., 785 F.3d 967, 973 (5th Cir. 2015): a Rule 41(a)(1)(A)(i) dismissal is “self-effectuating and terminates the case in and of itself; no order or other action of the district court is required.” This procedural mechanism is among the cleanest exits available in federal civil litigation.
Analyse de la liberté d'exploitation (FTO)
This case highlights critical IP risks in medical device testing equipment. Choose your next step:
📋 Comprendre l'impact de cette affaire
Découvrez les risques et les implications spécifiques liés à ce litige.
- View relevant patents in the ESU testing space
- Identify key companies active in medical device testing patents
- Understand competitive patenting strategies
🔍 Vérifier les risques liés à mon produit
Effectuez une analyse FTO complète pour votre propre technologie ou produit médical.
- Saisissez la description de votre produit ou ses caractéristiques techniques.
- L'IA identifie les brevets susceptibles de constituer un obstacle
- Obtenir un rapport d'évaluation des risques exploitable
Zone à haut risque
Electrosurgical unit (ESU) analyzer technology
Brevet actif
US 9,883,903 B1 remains enforceable
FTO proactif
Essential for new medical device products
✅ Points clés à retenir
Rule 41(a)(1)(A)(i) pre-answer dismissals are self-effectuating — no court order required, but with-prejudice status creates claim preclusion.
Rechercher la jurisprudence connexe →Co-plaintiff enforcement structures are increasingly common in specialized technology sectors like medical devices.
Explorer la veille concurrentielle →U.S. Patent No. 9,883,903 B1 remains an active enforcement asset; monitor for future assertions against other ESU analyzer manufacturers.
Suivre ce brevet →Foire aux questions
U.S. Patent No. 9,883,903 B1 (Application No. 14/702,385), covering technology relevant to electrosurgical unit testing and analysis.
Plaintiffs voluntarily dismissed under FRCP Rule 41(a)(1)(A)(i) before Datrend served an answer, a self-effectuating procedural right. The with-prejudice designation bars re-filing the same claims against Datrend.
The ‘903 patent remains active and enforceable against third parties. Other ESU analyzer manufacturers should assess FTO exposure; the dismissal provides no safe harbor beyond Datrend.
Prêt à renforcer votre stratégie en matière de brevets ?
Rejoignez plus de 18 000 professionnels de la propriété intellectuelle qui utilisent PatSnap Eureka pour effectuer des recherches d'antériorité, rédiger des brevets et analyser le paysage concurrentiel avec une précision optimisée par l'IA.
Références
- PACER — Case No. 1:23-cv-00998 (W.D. Tex.)
- U.S. Patent and Trademark Office — Patent 9,883,903 B1
- United States Court of Appeals for the Fifth Circuit — In re Amerijet Int’l, Inc., 785 F.3d 967, 973 (5th Cir. 2015)
- Institut d'information juridique de Cornell — Règle fédérale de procédure civile n° 41
- PatSnap — AI-native innovation intelligence platform
Cet article est publié à titre purement informatif et ne constitue en aucun cas un avis juridique. Toutes les informations relatives aux affaires sont tirées de dossiers judiciaires accessibles au public. Pour en savoir plus sur les fonctionnalités de la plateforme, rendez-vous sur PatSnap.